Browse categories and answer follow-up questions to refine your symptom profile.
Approach to the Critical Patient
Immediate priorities
Time-critical stabilization
Airway protection triggers
GCS 8 or less
Recurrent vomiting with aspiration risk
Hypoventilation
Refractory agitation preventing imaging
Breathing targets
Oxygen saturation 94% or higher
End-tidal CO2 35 to 40 mmHg if ventilated
Circulation priorities
Two large-bore IV access
Continuous ECG monitoring
Frequent neurologic reassessment trigger for resuscitation bay
Early high-risk identification
Aneurysmal SAH concern
Thunderclap headache peak intensity under 1 minute
Witnessed collapse or syncope
New seizure at onset
Meningismus
Focal neurologic deficit
Sentinel headache concern
Sudden severe headache days to weeks prior
Similar episode with spontaneous resolution
Hemodynamic goals
Physiologic targets
Systolic blood pressure target under 160 mmHg before aneurysm secured
Lower targets if ongoing bleeding concern and no ischemia concern
Avoid rapid large drops in chronic hypertension
Temperature under 38.0 C
Treat fever as secondary brain injury risk
Serum glucose 7.8 to 10.0 mmol/l
Avoid hypoglycemia
Euvolemia
Avoid hypotonic fluids
Avoid routine hypervolemia
Early consultation and pathway
Neurovascular activation
Neurosurgery early notification
Hydrocephalus concern
Declining mental status
Need for external ventricular drain
Interventional neuroradiology or endovascular team notification
CTA positive aneurysm
High suspicion with negative initial imaging
ICU disposition planning
Any confirmed SAH
Any depressed level of consciousness
Need for titratable BP agents
Transfer triggers
No neurosurgery or endovascular capability
Transfer after initial stabilization and imaging if feasible
BP control during transport
Airway secured prior to transport if unstable
History
Symptom pattern
Headache phenotype
Thunderclap onset
Peak intensity under 1 minute
Worst headache of life descriptor
Timing
Exact onset time for CT interpretation window
Duration and persistence
Associated symptoms
Syncope or near-syncope
Neck pain or stiffness
Photophobia
Nausea or vomiting
New seizure
Prodrome and warning leaks
Sentinel headache
Sudden severe headache in prior 1 to 4 weeks
Different from usual migraine pattern
Risk factors and triggers
Vascular and genetic risk
Known intracranial aneurysm
Family history of aneurysm or SAH
Polycystic kidney disease
Connective tissue disorder history
Ehlers-Danlos vascular type
Marfan syndrome
Acquired risk
Hypertension
Tobacco use
Cocaine or amphetamine exposure
Heavy alcohol use or binge
Antithrombotic exposure
Anticoagulant type and last dose time
Antiplatelet agents
Known bleeding disorder
Context and competing explanations
Trauma context
Head strike
High-risk mechanism
Anticoagulation with trauma
Alternative headache history
Known migraine pattern and typical aura
Prior thunderclap episodes
Exertional or sexual headache history
Physical Exam
Neurologic and meningeal findings
Neurologic screen
Level of consciousness
GCS trend
New confusion or agitation
Focal deficits
Cranial nerve palsy
Motor asymmetry
Aphasia
Neglect
Seizure activity
Ongoing convulsions
Postictal state
Meningeal irritation
Nuchal rigidity
Photophobia
Pain with neck flexion
General and cardiopulmonary
Vital signs pattern
Hypertension severity
Bradycardia with hypertension
Fever
Cardiac findings
Arrhythmia
Pulmonary edema signs
Stress cardiomyopathy concern
PITFALLS
Missed SAH patterns
Normal neurologic exam does not exclude SAH
Symptom improvement does not exclude aneurysmal leak
Migraine label with atypical thunderclap onset
Differential Diagnosis
Life-threatening causes of thunderclap headache
High-risk neurologic diagnoses
Subarachnoid hemorrhage
ICD-10 I60.0 to I60.9
SNOMED CT subarachnoid hemorrhage
Intracerebral hemorrhage
Cervical artery dissection
Cerebral venous sinus thrombosis
Reversible cerebral vasoconstriction syndrome
Pituitary apoplexy
Meningitis or encephalitis
Acute ischemic stroke with headache
High-risk systemic diagnoses
Hypertensive emergency with encephalopathy
Carbon monoxide toxicity
Acute angle-closure glaucoma
Mimics and lower-risk causes
Primary headache disorders
Migraine
Cluster headache
Primary thunderclap headache
Secondary benign causes
Viral syndrome headache
Sinusitis with severe pain
Medication overuse headache
Laboratory Tests
Baseline tests for SAH pathway
Initial labs
Complete blood count for anemia and platelet count
Thrombocytopenia threshold for procedure planning under 100 x 10^9/l
Electrolytes for hyponatremia risk
Serum sodium trend for cerebral salt wasting concern
Creatinine for contrast imaging safety
CTA feasibility
INR and aPTT for anticoagulation effect
Reversal planning if elevated
Type and screen
Potential neurosurgical intervention
Massive transfusion unlikely but peri-procedural planning
Cardiac and endocrine adjuncts
ECG and troponin consideration labs
Troponin for neurogenic myocardial injury concern
Prognostic association with worse outcomes
Pregnancy testing
All patients with pregnancy potential prior to imaging and meds
Lumbar puncture adjunct labs
Cerebrospinal fluid studies if LP performed
RBC count in serial tubes
Lack of reliable exclusion based on tube clearing alone
Xanthochromia testing if available
Supports SAH when present
Opening pressure
Elevated pressure supports alternative diagnoses like CVST
Diagnostic Tests
Scoring Systems
Clinical decision tools
Ottawa SAH rule for alert headache patients
Inclusion
New severe nontraumatic headache
Peak within 1 hour
Normal neurologic exam
High-risk features
Age 40 years or older
Neck pain or stiffness
Witnessed loss of consciousness
Onset during exertion
Thunderclap headache
Limited neck flexion on exam
Use case
Rule-out aid for selecting imaging
Not a standalone exclusion strategy
Severity grading after diagnosis
Hunt and Hess grade
Clinical grade for prognosis and communication
WFNS grade
GCS-based stratification
Fisher or modified Fisher grade
CT blood burden for vasospasm risk
MRI
MRI roles
Delayed presentation with negative CT and nondiagnostic LP
FLAIR and susceptibility sequences for blood products
Alternative diagnosis evaluation
CVST evaluation with MRV
Dissection evaluation with MRA
Limitations
Limited availability in unstable patients
Time and monitoring constraints in acute resuscitation
CT
Noncontrast CT head
First-line test for suspected SAH
Highest yield early after onset
Timing dependence
Highest sensitivity within 6 hours in modern multi-detector CT with expert interpretation
Sensitivity decreases with time from onset
Interpretation targets
Basal cistern blood
Sylvian fissure blood
Intraventricular hemorrhage
Hydrocephalus
CT angiography head and neck
Aneurysm detection after SAH confirmation
Aneurysm size and morphology
Multiple aneurysms possibility
Alternative diagnosis support
RCVS pattern
Dissection evaluation
ACEP acute headache guidance
Normal noncontrast CT within 6 hours in neurologically normal patient can exclude SAH in appropriate setting
ACEP Level B recommendation
If still at risk after negative CT
LP or CTA as next step
ACEP Level C recommendation
Ultrasound (or US)
Point-of-care ultrasound adjuncts
Cardiac POCUS
Stress cardiomyopathy pattern
Pulmonary edema association
Optic nerve sheath diameter
Elevated ICP screening adjunct
Not definitive for SAH diagnosis
IVC assessment
Volume status support for euvolemia goals
Disposition
Level of care
Admission requirements
All confirmed SAH
ICU or neuro-ICU level care
High suspicion pending workup
Ongoing severe headache with abnormal imaging plan
Need for serial neuro checks
Monitoring needs
Frequent neurologic checks
Strict BP control with IV titratable agents
Airway or ventilation support
Hydrocephalus concern
Transfer and definitive management site
Transfer criteria
Need for aneurysm securing
Endovascular coiling or surgical clipping capability
Need for EVD placement capability
Timing principles
Early aneurysm securing to prevent rebleeding
Avoid prolonged ED boarding without neurocritical monitoring
Treatment
Immediate measures
Supportive care bundle
Head of bed 30 degrees
Aspiration reduction
ICP reduction support
Analgesia and antiemesis
Avoid severe pain-driven hypertension
Avoid vomiting-driven ICP spikes
Stool softener consideration
Avoid Valsalva
Normothermia strategy
Acetaminophen
Surface cooling if refractory
Blood pressure management before aneurysm secured
IV antihypertensives
Nicardipine infusion
Initiate 5 mg/hour
Titration 2.5 mg/hour every 5 to 15 minutes
Maximum 15 mg/hour
Monitoring
Continuous BP
Hypotension avoidance
Clevidipine infusion
Initiate 1 to 2 mg/hour
Titration doubling every 90 seconds to 3 minutes initially
Then titration small increments every 5 to 10 minutes
Contraindications
Allergy to egg or soy products
Defective lipid metabolism syndrome
Labetalol IV bolus
Initiate 10 to 20 mg slow IV
Repeat 10 to 20 mg every 10 minutes as needed
Typical cumulative maximum 300 mg
Contraindications
Severe asthma with bronchospasm
Bradycardia with hypotension
Rebleeding prevention and aneurysm securing pathway
Antifibrinolytic short-course in select patients
Indication
High rebleeding risk with delayed aneurysm securing
Tranexamic acid IV example regimen
Initiate 1 g IV
Then 1 g IV every 6 to 8 hours
Stop once aneurysm secured
Risks
Thromboembolism concern
DCI risk concern
Definitive aneurysm management
Endovascular coiling
Preferred in many anatomies and older patients
Surgical clipping
Consider for certain aneurysm morphologies
Guideline alignment
Early aneurysm securing recommended in aneurysmal SAH
Class I recommendation in major society guidance
Delayed cerebral ischemia and vasospasm prevention
Nimodipine
Oral regimen
Initiate 60 mg PO every 4 hours
Duration 21 days
Dose reduction strategy if hypotension
Evidence
Improves neurologic outcomes after aneurysmal SAH
Class I recommendation in major society guidance
Volume strategy
Euvolemia target
Isotonic crystalloids
Avoid prophylactic hypervolemia
Hydrocephalus and elevated ICP
Acute hydrocephalus management
External ventricular drain
Neurosurgery placement
CSF diversion with ICP monitoring
Temporizing measures if herniation concern
Hypertonic saline bolus protocol per institutional policy
Avoid hypotonic fluids
Seizure management
Acute seizure treatment
Benzodiazepine first-line
Lorazepam IV 0.1 mg/kg
Maximum 4 mg per dose
Repeat once if needed
Second-line antiseizure medication
Levetiracetam IV 60 mg/kg
Maximum 4.5 g
Prophylaxis considerations
Short-course prophylaxis in high-risk features
Intraparenchymal hematoma
Cortical involvement
Early seizure
Routine long-course prophylaxis avoidance
Adverse effect and limited benefit concern
Antithrombotic reversal and hemostasis
Warfarin reversal
4-factor PCC
Dose per INR and weight per local protocol
Vitamin K IV
5 to 10 mg IV
Dabigatran reversal
Idarucizumab
5 g IV total
Two 2.5 g doses
Factor Xa inhibitor reversal
Andexanet alfa if available
Dosing based on agent and last dose timing
4-factor PCC alternative
Institutional protocol dosing
Platelet issues
Platelet transfusion considerations
Severe thrombocytopenia with procedure planned
Antiplatelet reversal strategy individualized with neurosurgery
Special Populations
Pregnancy
Pregnancy-specific considerations
Differential emphasis
Preeclampsia and eclampsia
CVST risk increase
Imaging approach
Noncontrast CT head acceptable when clinically indicated
Shielding and dose minimization principles
Medication safety
Nimodipine risk-benefit discussion with obstetrics
Labetalol and hydralazine commonly used for BP control
Consultation
Obstetrics and maternal-fetal medicine early involvement
Geriatric
Older adult considerations
Higher baseline aneurysm prevalence
Higher procedural risk
Increased susceptibility to hypotension from antihypertensives
Delirium risk with sedatives and opioids
Goals of care discussions early when poor-grade SAH
Pediatrics
Pediatric SAH features
Lower aneurysmal proportion than adults
AVM and trauma proportion higher
Dosing approach
Weight-based medication dosing
Benzodiazepines
Levetiracetam
BP targets individualized with pediatric critical care
Imaging considerations
Radiation minimization
Early neurosurgery and pediatric neurocritical care involvement
Background
Epidemiology
Burden and outcomes
Aneurysmal SAH is a cause of sudden severe headache with high morbidity
Early rebleeding risk highest in first 24 hours without aneurysm securing
Vasospasm and delayed cerebral ischemia common contributors to poor outcome
Risk factor associations
Hypertension association with aneurysm formation and rupture
Tobacco use association with aneurysm rupture risk
Family history association with aneurysm prevalence
Pathophysiology
Bleeding source categories
Aneurysmal rupture into subarachnoid space
Traumatic SAH
ICD-10 S06.6X
Nonaneurysmal perimesencephalic hemorrhage
AVM or dural AV fistula hemorrhage
Secondary injury mechanisms
Global cerebral edema
Hydrocephalus from impaired CSF resorption
Vasospasm and microthrombosis
Cortical spreading depolarizations
Neurogenic cardiac injury and pulmonary edema
Therapeutic Considerations
Time-dependent priorities
Early aneurysm securing to prevent rebleeding
Nimodipine to improve neurologic outcomes
Euvolemia to support cerebral perfusion
BP strategy logic
High BP associated with rebleeding risk
Excessive lowering risks cerebral hypoperfusion
DCI management concepts
Clinical monitoring for new deficits
Rescue strategies in ICU settings
Induced hypertension after aneurysm secured
Endovascular therapy for refractory vasospasm
Patient Discharge Instructions
copy discharge instructions
Discharge instructions for negative SAH evaluation
Return now for red flags
Sudden severe headache recurrence
Fainting or near-fainting
New weakness
New numbness
New trouble speaking
New vision changes
New seizure
Persistent vomiting
Fever with stiff neck
Confusion or worsening drowsiness
Activity
Avoid heavy exertion until follow-up if symptoms not fully resolved
Medications
Avoid new anticoagulants unless prescribed by clinician
Follow-up
Primary care or neurology follow-up within 48 to 72 hours if headache persists
Immediate follow-up for recurrent thunderclap headache
References
Clinical guidelines and key evidence
Major society guideline sources
American Heart Association and American Stroke Association guideline for aneurysmal subarachnoid hemorrhage management
Recommendations for early aneurysm securing
Recommendations for nimodipine
Recommendations for DCI monitoring and treatment
Neurocritical care society guidance for SAH management principles
ICU monitoring standards
EVD and hydrocephalus management principles
Emergency medicine clinical policy sources
ACEP clinical policy on acute headache
Noncontrast CT within 6 hours in neurologically normal patient as exclusion strategy
Next-step testing options after negative CT when risk persists
Decision tool evidence
Ottawa SAH rule derivation and validation studies
High sensitivity in eligible populations
Limited specificity requiring clinical judgment
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.